Newer antidiabetic agents including SGLT1/2 (sodium-glucose co- transporter-1/2) inhibitors and GLP-1R (glucagon-like peptide 1 receptor) agonists are being tested in NASH. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatohepatitis.